RMD
$112.61
Resmed
($.82)
(.72%)
Earnings Details
4th Quarter June 2018
Thursday, August 2, 2018 4:05:00 PM
Tweet Share Watch
Summary

Resmed (RMD) Recent Earnings

Resmed (RMD) reported 4th Quarter June 2018 earnings of $0.95 per share on revenue of $623.6 million. The consensus earnings estimate was $0.90 per share on revenue of $616.4 million. Revenue grew 12.0% on a year-over-year basis.

ResMed Inc is a developer, manufacturer and distributor of medical products for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders.

Results
Reported Earnings
$0.95
Earnings Whisper
-
Consensus Estimate
$0.90
Reported Revenue
$623.6 Mil
Revenue Estimate
$616.4 Mil
Growth
Earnings Growth
Revenue Growth
Power Rating
Grade
Earnings Release

ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2018

  • Revenue increased 12% to $623.6 million; up 10% on a constant currency basis
  • Net income increased by 8%; non-GAAP net income up 24%
  • GAAP diluted earnings per share of $0.76; non-GAAP diluted earnings per share of $0.95
  • Operating cash flow of $129.4 million in the fourth quarter
  • Quarterly dividend increased by 6% to $0.37 per share

SAN DIEGO--(BUSINESS WIRE)-- ResMed Inc. (NYSE: RMD) (ASX: RMD) today announced results for its quarter ended June 30, 2018. Revenue for the quarter was $623.6 million, a 12 percent increase compared to the same period of the prior year.

“We closed out the year with strong performance across all aspects of our business, from solid top-line revenue growth - driven by geographically balanced results across our entire portfolio of offerings - to continued improvements in operating leverage, which has resulted in double-digit bottom-line growth,” said Mick Farrell, ResMed’s chief executive officer.

“We continue to advance our cloud-connected medical device strategy and are growing our cloud-based software-as-a-service business. Our clinical studies and research efforts are being recognized and the opportunity to increase awareness of sleep-related breathing disorders and improve patient quality of life is bigger than ever.”

Farrell concluded, “We believe we are well-positioned as we enter fiscal year 2019. We continue to innovate, we are improving our existing portfolio of products and offerings, and we have a robust pipeline to drive future growth.”

Analysis of fourth quarter results

Fourth quarter revenue in U.S., Canada and Latin America, excluding Brightree, was $346.7 million, a 10 percent increase over the same period of the prior year. Brightree revenue for the fourth quarter was $40.4 million, an increase of 12 percent compared to the same period of the prior year. Revenue in combined Europe, Asia and other markets was $236.5 million, an increase of 9 percent on a constant currency basis, compared to the same period of the prior year.

Gross margin in the fourth quarter was 58.1 percent, lower than the prior year’s quarter gross margin of 58.2 percent mainly due to declines in average selling prices, which were partially offset by manufacturing and procurement efficiencies.

Income from operations for the quarter was $146.9 million, a 15 percent increase compared with the quarter ended June 30, 2017. Non-GAAP income from operations for the quarter was $166.0 million, a 19 percent increase compared to the same period of the prior year.

Selling, general and administrative expenses were $156.8 million, a 6 percent increase over the same period in the prior year, or a 3 percent increase on a constant currency basis. SG&A expenses improved to 25.1 percent of revenue in the quarter, compared with 26.6 percent reported in the quarter ended June 30, 2017.

Research and development expenses were $39.7 million, or 6.4 percent of revenue. R&D expenses increased by 8 percent compared with the same period last year, or a 6 percent increase on a constant currency basis.

Amortization of acquired intangible assets was $11.6 million during the quarter, which is consistent with the same period last year. Stock-based compensation costs incurred during the quarter of $12.5 million consisted of expenses associated with employee equity grants and our employee stock purchase plan.

Net income for the quarter was $109.8 million, an 8 percent increase compared to the same period of the prior year. Non-GAAP net income was $136.3 million, a 24 percent increase compared to the prior year.

Non-GAAP measures adjust for amortization of acquired intangibles, impact of U.S. tax reform on income tax expense, restructuring expenses and impact of foreign tax credit adjustments on income tax expense.

GAAP diluted earnings per share for the quarter increased by 7 percent to $0.76. Non-GAAP diluted earnings per share of $0.95 were 23 percent higher compared with the same period of the prior year.

Cash flow from operations for the quarter was $129.4 million compared to net income in the current quarter of $109.8 million. During the quarter we paid $50.0 million in dividends.

Impact of U.S. tax reform on income tax expense

On December 22, 2017 “H.R.1”, originally known as the Tax Cuts and Jobs Act, was enacted into law (“U.S. tax reform”). ASC 740 Income Taxes requires companies to recognize the effect of any tax laws during the period in which they are enacted. Accordingly, during the quarter ended December 31, 2017, we performed preliminary calculations which have been refined during the remainder of the fiscal year. Based on these refinements, and additional guidance from the U.S. Internal Revenue Service, we recognized additional income tax expense of $5.8 million during the three months ended June 30, 2018 for a total income tax expense of $138.0 million during the year ended June 30, 2018.

The U.S. tax reform significantly revises the U.S. corporate income tax by, among other things, imposing a one-time transition tax on unremitted foreign earnings, lowering the corporate income tax rate from 35 percent to 21 percent and implementing a territorial tax system in relation to foreign earnings.

Analysis of fiscal year 2018 results

Revenue for the year increased 13 percent over the prior year to $2.3 billion, or a 10 percent increase on a constant currency basis.

Income from operations for the year was $541.8 million, a 27 percent increase over the prior year. Non-GAAP income from operations for the year was $606.6 million, a 19 percent increase over the prior year.

Non-GAAP measures adjust for amortization of acquired intangibles, impact of U.S. tax reform on income tax expense, restructuring expenses, impact of foreign tax credit adjustments on income tax expense, litigation settlement expenses, acquisition related expenses and the Astral battery field safety notification expenses.

Net income for the year was $315.6 million, an 8 percent decrease over the prior year. Non-GAAP net income was $507.8 million, a 27 percent increase compared to the prior year.

GAAP diluted earnings per share decreased 9 percent to $2.19. Non-GAAP diluted earnings per share for the year was $3.53, a 25 percent increase compared with the prior year.

Cash flow from operations for the year was $505.0 million. During the year we paid $199.5 million in dividends and repaid a net amount of $796.2 million of our outstanding debt.

Debt refinancing

As reported during the previous quarter, on April 17, 2018, we entered into a new unsecured syndicated facility (“Facility”) that provides for an $800 million five-year revolving Credit Facility and a $200 million five-year Term Loan. The proceeds from the initial funding of the Term Loan were used to repay a portion of the outstanding balance of the Credit Facility.

Share repurchase program

During the quarter, we repurchased 250,000 shares at a cost of $25.9 million, as part of our ongoing capital management program.

Dividend program

The ResMed board of directors today declared quarterly cash dividend of $0.37 per share. The dividend will have a record date of August 16, 2018, payable on September 20, 2018. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be August 15, 2018 for common stock holders and for CDI holders. ResMed has received a waiver from the ASX's settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from August 15, 2018 through August 16, 2018, inclusive.

Webcast details

ResMed will discuss its fourth quarter fiscal year 2018 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on ResMed's Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q4 2018 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on our website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately two hours after the webcast by dialing 800-585-8367 (U.S.) and +1 416-621-4642 (outside U.S.) and entering a passcode of 7796686. The telephone replay will be available until August 16, 2018.

About ResMed

ResMed (NYSE: RMD) (ASX: RMD), a world-leading connected health company with more than 5 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-member team strives to improve patients’ quality of life, reduce the impact of chronic disease and save healthcare costs in more than 120 countries.

Safe harbor statement

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, leveraging of strategic investments, litigation, and tax outlook – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed’s periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.

       

RESMED INC AND SUBSIDIARIES

Condensed Consolidated Statements of Income (Unaudited)

(In thousands, except per share data)

                         
Three Months Ended Twelve Months Ended
June 30, June 30,
      2018       2017       2018       2017  
 
Net revenue $ 623,631 $ 556,686 $ 2,340,196 $ 2,066,737
Cost of sales 261,159 232,910 978,032 859,922
Astral field safety notification expenses (1)     -       -       -       5,070  
Gross profit     362,472       323,776       1,362,164       1,201,745  
 
Operating expenses:
Selling, general and administrative 156,810 147,940 600,369 553,968
Research and development 39,657 36,706 155,149 144,467
Amortization of acquired intangible assets (1) 11,611 11,769 46,383 46,578
Restructuring expenses (1) 7,510 - 18,432 12,358
Litigation settlement expenses (1) - - - 8,500
Acquisition related expenses (1)     -       -       -       10,076  
Total operating expenses     215,588       196,415       820,333       775,947  
Income from operations (1)     146,884       127,361       541,831       425,798  
 
Other income (expenses), net:
Interest income (expense), net (2,780 ) (3,310 ) (11,977 ) (11,151 )
Other, net     (3,185 )     (2,428 )     (8,542 )     4,096  
Total other income (expenses), net     (5,965 )     (5,738 )     (20,519 )     (7,055 )
Income before income taxes 140,919 121,623 521,312 418,743
Income taxes (1)     31,107       20,010       205,724       76,459  
Net income (1)   $ 109,812     $ 101,613     $ 315,588     $ 342,284  
 
Basic earnings per share $ 0.77 $ 0.72 $ 2.21 $ 2.42
Diluted earnings per share $ 0.76 $ 0.71 $ 2.19 $ 2.40
Non-GAAP diluted earnings per share (1) $ 0.95 $ 0.77 $ 3.53 $ 2.82
 
Basic shares outstanding 142,793 142,019 142,764 141,360
Diluted shares outstanding     144,004       143,119       143,987       142,453  
 

(1) See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

 
   

RESMED INC AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited - In thousands)

             
June 30, June 30,
      2018       2017  
ASSETS
Current assets:
Cash and cash equivalents $ 188,701 $ 821,935
Accounts receivable, net 483,681 450,530
Inventories 268,701 268,319
Prepayments and other current assets     124,634       103,219  
Total current assets     1,065,717       1,644,003  
Property, plant and equipment, net 386,550 394,241
Goodwill 1,068,944 1,064,874
Other intangibles, net 215,184 261,800
Deferred income taxes and other non-current assets     327,528       103,569  
Total non-current assets     1,998,206       1,824,484  
Total assets   $ 3,063,923     $ 3,468,487  
LIABILITIES AND STOCKHOLDERS’ EQUITY:
Current liabilities:
Accounts payable 92,723 92,763
Accrued expenses 185,805 186,295
Deferred revenue 60,828 51,918
Income taxes payable 160,427 29,150
Short-term debt     11,466       -  
Total current liabilities     511,249       360,126  
Non-current liabilities:
Deferred revenue 71,596 53,235
Deferred income taxes 13,084 13,822
Other long term liabilities 924 2,427
Long-term debt 269,988 1,078,611
Long-term income taxes payable     138,102       -  
Total non-current liabilities     493,694       1,148,095  
Total liabilities     1,004,943       1,508,221  
STOCKHOLDERS’ EQUITY:
Common stock 571 569
Additional paid-in capital 1,450,821 1,379,130
Retained earnings 2,432,328 2,316,237
Treasury stock (1,600,412 ) (1,546,611 )
Accumulated other comprehensive income     (224,328 )     (189,059 )
Total stockholders’ equity   $ 2,058,980     $ 1,960,266  
Total liabilities and stockholders' equity   $ 3,063,923     $ 3,468,487  
 
   

RESMED INC AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Unaudited - In thousands)

             
Twelve Months Ended
June 30,
      2018       2017  
Cash flows from operating activities:
Net income $ 315,588 $ 342,284
Adjustment to reconcile net income to cash provided by operating activities:
Depreciation and amortization 119,960 112,157
Stock-based compensation costs 48,412 45,925
Impairment of cost-method investments 11,593 1,955
Changes in fair value of business combination contingent consideration 411 10,076
Payment of business combination contingent consideration - (8,460 )
Changes in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net (32,356 ) (63,604 )
Inventories, net 1,494 (41,599 )
Prepaid expenses, net deferred income taxes and other current assets (160,726 ) (19,257 )
Accounts payable, accrued expenses and other liabilities     200,650       34,576  
Net cash provided by operating activities     505,026       414,053  
Cash flows from investing activities:
Purchases of property, plant and equipment (62,581 ) (62,219 )
Patent registration costs (8,876 ) (9,257 )
Business acquisitions, net of cash acquired (902 ) (7,274 )
Investments in cost-method investments (14,495 ) (6,464 )
Proceeds / (Payments) on maturity of foreign currency contracts     (14,970 )     3,324  
Net cash used in investing activities     (101,824 )     (81,890 )
Cash flows from financing activities:
Proceeds from issuance of common stock, net 23,332 30,161
Purchases of treasury stock (53,801 ) -
Payment of business combination contingent consideration (486 ) (11,682 )
Proceeds from borrowings, net of borrowing costs 350,000 450,000
Repayment of borrowings (1,146,242 ) (545,000 )
Dividends paid     (199,497 )     (186,346 )
Net cash (used in) / provided by financing activities     (1,026,694 )     (262,867 )
Effect of exchange rate changes on cash     (9,742 )     21,205  
Net increase / (decrease) in cash and cash equivalents (633,234 ) 90,501
Cash and cash equivalents at beginning of period     821,935       731,434  
Cash and cash equivalents at end of period   $ 188,701     $ 821,935  
 
       
Reconciliation of Non-GAAP Financial Measures (Unaudited)

(In US$ thousands, except share and per share data)

 

The measure, "non-GAAP income from operations" is reconciled with GAAP income from operations below:

Three Months Ended Twelve Months Ended
June 30, June 30,
      2018     2017     2018     2017
GAAP income from operations $ 146,884 $ 127,361 $ 541,831 $ 425,798
Amortization of acquired intangible assets (A) 11,611 11,769 46,383 46,578
Restructuring expenses (A) 7,510 - 18,432 12,358
Litigation settlement expenses (A) - - - 8,500
Acquisition related expenses (A) - - - 10,076
Astral battery field safety notification expenses (A)     -     -     -     5,070
Non-GAAP income from operations   $ 166,005   $ 139,130   $ 606,646   $ 508,380
 
The measures "non-GAAP net income" and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:
Three Months Ended Twelve Months Ended
June 30, June 30,
      2018     2017     2018     2017
GAAP net income $ 109,812 $ 101,613 $ 315,588 $ 342,284
Amortization of acquired intangible assets, net of tax (A) 8,435 7,999 33,694 31,679
U.S. tax reform transition impact (A) 1,380 - 126,881 -
U.S. tax reform impact on deferred taxes (A) 4,412 - 11,135 -
Restructuring expenses, net of tax (A) 5,013 - 13,328 8,295
Foreign tax credit adjustment (A) 7,204 - 7,204 -
Litigation settlement expenses, net of tax (A) - - - 5,392
Acquisition related expenses (A) - - - 10,076
Astral battery field safety notification expenses (A)     -     -     -     3,549
Non-GAAP net income (A)   $ 136,256   $ 109,612   $ 507,830   $ 401,275
Diluted shares outstanding     144,004     143,119     143,987     142,453
GAAP diluted earnings per share   $ 0.76   $ 0.71   $ 2.19   $ 2.40
Non-GAAP diluted earnings per share (A)   $ 0.95   $ 0.77   $ 3.53   $ 2.82
 
(A)   ResMed adjusts for the impact of the amortization of acquired intangibles, impact of U.S. tax reform on income tax expense, restructuring expenses, impact of foreign tax credit adjustments on income tax expense, litigation settlement expenses, acquisition related expenses and the Astral battery field safety notification expenses, from their evaluation of ongoing operations and believes investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.
 
ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight in evaluating ResMed’s performance from core operations and provides consistent financial reporting. Our use of non-GAAP measures is intended to supplement, and not to replace, our presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

ResMed Inc.
For investors
Amy Wakeham
O: 858-836-5000
investorrelations@resmed.com
or
For media
Jayme Rubenstein
O: 858-836-6798
news@resmed.com

Source: ResMed Inc.